Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...
The PREVENT tool — the newest cardiovascular risk calculator — makes individual dialogue between doctor and patient more ...
"Variations in the use of secondary CVD prevention medications over time in our contemporary cohort study suggest little to no improvement globally." HealthDay News — Use of secondary cardiovascular ...
Please provide your email address to receive an email when new articles are posted on . Many people requiring secondary prevention drugs for CVD do not receive them. This trend persisted even in ...
Clonal hematopoiesis of indeterminate potential was not associated with an increased risk for heart disease but was linked to ...
Broader uptake of single-pill combination (SPC) therapies—polypills—to simplify primary or secondary prevention of cardiovascular disease could have a huge impact on a global scale in the coming ...
Across the world, many patients with CVD still aren’t on the recommended medications for secondary prevention, according to more than a decade’s worth of data from the 17-country Prospective Urban ...
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma1 compellingly reframes coronary artery disease as a lifelong continuum, advocating for early prevention ...
Heart disease is the No. 1 cause of death in the United States. These are the steps you need to take to reduce your risk.
People who caught the flu were up to six times more likely to have a heart attack in the month after the infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback